After an elevated prostate-specific antigen (PSA) test, which helped screen for prostate cancer, left him reeling, longtime ...

Innovative technology performs automatic segmentation and lesion detection in prostate MRI scans to assist in PI-RADS scoring for prostate cancer management TEL AVIV, Israel & SAN JOSE, ...

Thanks to early detection and aggressive treatment for prostate cancer, 97 percent of all men diagnosed with the disease will survive at least 5 years and nearly 80 percent will survive at least a ...

Researchers at the Icahn School of Medicine at Mount Sinai have developed an advanced artificial intelligence (AI)-driven tool to improve the management and prognosis of prostate cancer. Recent ...

Test Now Incorporates Enhanced Machine Learning Risk Prediction Algorithm Plans Underway to Commercialise Testing Service Through Trinity Biotech’s New York Reference Laboratory DUBLIN and NEW YORK, ...

The diagnostic imaging provider RadNet has secured two software clearances from the FDA to help radiologists spot cases of breast and prostate cancer. The programs were developed by its artificial ...

Prostate cancer is the second-leading cause of cancer death in American men. About 1 in 8 men will be diagnosed with prostate cancer in their lifetime, and the risk varies depending on age and race.

Researcher in lab An AI tool outperformed NCCN guidelines for predicting biochemical failure, distant metastasis, prostate cancer-specific survival, and overall survival. An artificial intelligence ...

Women’s HRT patches control prostate cancer as well as standard hormone injections, but with fewer hot flushes and less bone ...

As part of its Speaking Out video series, on behalf of Fans for the Cure, CURE® spoke with Dr. Daniel P. Petrylak about PSMA, what it is and how it is advancing the prostate cancer landscape. Kristie ...

A randomized phase III trial run out of the United Kingdom has found that estradiol skin patches suppress testosterone as ...

Digital rectal examination (DRE) is neither helpful nor useful as a solitary prostate cancer screening tool in middle-aged men, say investigators reporting the PROBASE study. The study compared ...